New courses at cancer institute

The region's premier cancer hospital, Dr B Borooah Cancer Institute(BBCI), has become the only institute in the whole of eastern India to be granted permission by the ministry of health and family welfare to initiate post doctorate super speciality courses in oncology.

Cancer experts have hailed the latest development as introduction of new courses in cancer studies will help bridge the gap emanating from shortage of doctors and manpower since Assam and the northeast are home to a burgeoning number of cancer patients.

Based on estimates of data collected from cancer cases and government reports on the projected population of 2026, there could be 26,973 new cancer cases across Assam among both men and women in 11 years.


BBCI will initiate the super speciality course from the present academic session 2017-18. With the initiation of the latest course, BBCI has now added another feather to its cap as the Medical Council of India had already granted permission to start post doctorate super speciality courses in radiation oncology, which was given four years ago and surgical oncology given last year.
"BBCI has become the only institute in eastern India to have three disciplines of oncology. There is an acute shortage of oncologists in the northeast. With the introduction of such courses, the manpower shortage in oncology can be overcome," said Amal Chandra Kataki, director, BBCI.


Currently, post doctorate super speciality course in medical oncology is offered in 19 institutions across states like Maharashtra, Andhra Pradesh, Delhi, Gujarat, Karnataka, Tamil Nadu and Kerala.

Source:http://timesofindia.indiatimes.com/city/guwahati/new-courses-at-cancer-institute/articleshow/58390463.cms

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more